Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics

An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine

(2021) Michelle Whirl‐Carrillo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)

(2021) Maja Matic et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Editorial: From Trial and Error to Individualised Pharmacogenomics-Based Pharmacotherapy in Psychiatry

(2021) R. van Westrhenen et al.   Frontiers in Pharmacology

Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?

(2020) Roos van Westrhenen et al.   Frontiers in Psychiatry

Standardizing CYP 2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group

(2019) Kelly E. Caudle et al.   CTS-Clinical and Translational Science

Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications

(2019) Lauren A. Marcath et al.   PHARMACOGENOMICS JOURNAL

Pharmacogenetic Information in Clinical Guidelines: The European Perspective

(2018) Jesse J. Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenomics, a novel section in the European Journal of Human Genetics

(2018) Henk-Jan Guchelaar   EUROPEAN JOURNAL OF HUMAN GENETICS

Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy

(2014) M. Apellaniz-Ruiz et al.   CLINICAL CANCER RESEARCH

The Influence of the CYP3A4*22 Polymorphism on Serum Concentration of Quetiapine in Psychiatric Patients

(2014) Karen van der Weide et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Cytochrome P450 variations in different ethnic populations

(2012) Joseph McGraw et al.   Expert Opinion on Drug Metabolism & Toxicology

Pharmacogenetic tests: the need for a level playing field

(2012) Munir Pirmohamed et al.   NATURE REVIEWS DRUG DISCOVERY

The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients

(2012) Laure Elens et al.   Pharmacogenetics and Genomics

A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients

(2011) L. Elens et al.   CLINICAL CHEMISTRY

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

(2011) J J Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study

(2011) Laure Elens et al.   Pharmacogenetics and Genomics

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

(2010) D Wang et al.   PHARMACOGENOMICS JOURNAL

Pharmacogenetics: From Bench to Byte

(2008) JJ Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS